Works matching AU Saito, Haruhiro

Results: 68
    1
    2

    A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study.

    Published in:
    Clinical Lung Cancer, 2024, v. 25, n. 3, p. 266, doi. 10.1016/j.cllc.2024.03.003
    By:
    • Garon, Edward B.;
    • Byoung Chul Cho;
    • Luft, Alexander;
    • Alatorre-Alexander, Jorge;
    • Geater, Sarayut Lucien;
    • Dmytro Trukhin;
    • Sang-We Kim;
    • Ursol, Grygorii;
    • Hussein, Maen;
    • Louise Lim, Farah;
    • Cheng-Ta Yang;
    • Araujo, Luiz Henrique;
    • Haruhiro Saito;
    • Reinmuth, Niels;
    • Kohlmann, Milena;
    • Lowery, Caitlin;
    • Mann, Helen;
    • Peters, Solange;
    • Mok, Tony S.;
    • Johnson, Melissa L.
    Publication type:
    Article
    3

    A Phase II Study of Ubenimex Combined With Pembrolizumab, Nab-Paclitaxel, and Carboplatin for Previously Untreated Advanced Squamous Non-Small-Cell Lung Cancer: TORG2241 (UBE-Q).

    Published in:
    Clinical Lung Cancer, 2024, v. 25, n. 1, p. 85, doi. 10.1016/j.cllc.2023.09.006
    By:
    • Shinji Nakamichi;
    • Kaoru Kubota;
    • Kotone Matsuyama;
    • Toshihiro Misumi;
    • Toshiyuki Kozuki;
    • Shunichi Sugawara;
    • Katsuhiko Naoki;
    • Nobuaki Kobayashi;
    • Takehito Shukuya;
    • Tsuneo Shimokawa;
    • Masashi Ishihara;
    • Hiroshi Wakui;
    • Yukio Hosomi;
    • Hiroshi Tanaka;
    • Haruhiro Saito;
    • Shinobu Hosokawa;
    • Yuichi Takiguchi;
    • Takashi Kasai;
    • Hiroshi Nokihara;
    • Ryo Morita
    Publication type:
    Article
    4
    5

    First-line nivolumab plus ipilimumab with or without chemotherapy for Japanese patients with non-small cell lung cancer: LIGHT-NING study.

    Published in:
    Japanese Journal of Clinical Oncology, 2024, v. 54, n. 4, p. 452, doi. 10.1093/jjco/hyad195
    By:
    • Imai, Hisao;
    • Kijima, Takashi;
    • Azuma, Koichi;
    • Kishi, Kazuma;
    • Saito, Haruhiro;
    • Yamaguchi, Teppei;
    • Tanizaki, Junko;
    • Yoneshima, Yasuto;
    • Fujita, Kohei;
    • Watanabe, Satoshi;
    • Kitazono, Satoru;
    • Fukuhara, Tatsuro;
    • Hataji, Osamu;
    • Toi, Yukihiro;
    • Mizutani, Hideaki;
    • Hamakawa, Yusuke;
    • Maemondo, Makoto;
    • Ohsugi, Tomoyuki;
    • Suzuki, Keisuke;
    • Horinouchi, Hidehito
    Publication type:
    Article
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23

    Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (West Japan Oncology Group 5910L): An open-label, randomized, phase 2 trial.

    Published in:
    2016
    By:
    • Takeda, Masayuki;
    • Yamanaka, Takeharu;
    • Seto, Takashi;
    • Hayashi, Hidetoshi;
    • Azuma, Koichi;
    • Okada, Morihito;
    • Sugawara, Shunichi;
    • Daga, Haruko;
    • Hirashima, Tomonori;
    • Yonesaka, Kimio;
    • Urata, Yoshiko;
    • Murakami, Haruyasu;
    • Saito, Haruhiro;
    • Kubo, Akihito;
    • Sawa, Toshiyuki;
    • Miyahara, Eiji;
    • Nogami, Naoyuki;
    • Nakagawa, Kazuhiko;
    • Nakanishi, Yoichi;
    • Okamoto, Isamu
    Publication type:
    journal article
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33
    34

    Association between soluble immune mediators and tumor responses in patients with nonsmall cell lung cancer treated with anti‐PD‐1 inhibitor.

    Published in:
    International Journal of Cancer, 2019, v. 144, n. 5, p. 1170, doi. 10.1002/ijc.31923
    By:
    • Matsuo, Norikazu;
    • Azuma, Koichi;
    • Hattori, Satoshi;
    • Ohtake, Junya;
    • Kawahara, Akihiko;
    • Ishii, Hidenobu;
    • Tokito, Takaaki;
    • Yamada, Kazuhiko;
    • Shibata, Yuji;
    • Shimokawaji, Tadasuke;
    • Kondo, Tetsuro;
    • Kato, Terufumi;
    • Saito, Haruhiro;
    • Yamada, Kouzo;
    • Sasada, Tetsuro;
    • Hoshino, Tomoaki
    Publication type:
    Article
    35

    Multi-omics analysis-based clinical and functional significance of a novel prognostic and immunotherapeutic gene signature derived from amino acid metabolism pathways in lung adenocarcinoma.

    Published in:
    Frontiers in Immunology, 2024, p. 1, doi. 10.3389/fimmu.2024.1361992
    By:
    • Xiang, Huihui;
    • Kasajima, Rika;
    • Azuma, Koichi;
    • Tagami, Tomoyuki;
    • Hagiwara, Asami;
    • Nakahara, Yoshiro;
    • Saito, Haruhiro;
    • Igarashi, Yuka;
    • Wei, Feifei;
    • Ban, Tatsuma;
    • Yoshihara, Mitsuyo;
    • Nakamura, Yoshiyasu;
    • Sato, Shinya;
    • Koizume, Shiro;
    • Tamura, Tomohiko;
    • Sasada, Tetsuro;
    • Miyagi, Yohei
    Publication type:
    Article
    36

    Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M–positive non–small cell lung cancer: West Japan Oncology Group 8815L/LPS study.

    Published in:
    Cancer (0008543X), 2020, v. 126, n. 9, p. 1940, doi. 10.1002/cncr.32749
    By:
    • Takahama, Takayuki;
    • Azuma, Koichi;
    • Shimokawa, Mototsugu;
    • Takeda, Masayuki;
    • Ishii, Hidenobu;
    • Kato, Terufumi;
    • Saito, Haruhiro;
    • Daga, Haruko;
    • Tsuboguchi, Yuko;
    • Okamoto, Isamu;
    • Otsubo, Kohei;
    • Akamatsu, Hiroaki;
    • Teraoka, Shunsuke;
    • Takahashi, Toshiaki;
    • Ono, Akira;
    • Ohira, Tatsuo;
    • Yokoyama, Toshihide;
    • Sakai, Kazuko;
    • Yamamoto, Nobuyuki;
    • Nishio, Kazuto
    Publication type:
    Article
    37

    Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M-positive non-small cell lung cancer: West Japan Oncology Group 8815L/LPS study.

    Published in:
    2020
    By:
    • Takahama, Takayuki;
    • Azuma, Koichi;
    • Shimokawa, Mototsugu;
    • Takeda, Masayuki;
    • Ishii, Hidenobu;
    • Kato, Terufumi;
    • Saito, Haruhiro;
    • Daga, Haruko;
    • Tsuboguchi, Yuko;
    • Okamoto, Isamu;
    • Otsubo, Kohei;
    • Akamatsu, Hiroaki;
    • Teraoka, Shunsuke;
    • Takahashi, Toshiaki;
    • Ono, Akira;
    • Ohira, Tatsuo;
    • Yokoyama, Toshihide;
    • Sakai, Kazuko;
    • Yamamoto, Nobuyuki;
    • Nishio, Kazuto
    Publication type:
    journal article
    38
    39

    Circulating IL-6 and not its circulating signaling components sIL-6R and sgp130 demonstrate clinical significance in NSCLC patients treated with immune checkpoint inhibitors.

    Published in:
    Frontiers in Cell & Developmental Biology, 2024, p. 1, doi. 10.3389/fcell.2023.1324898
    By:
    • Yoshiro Nakahara;
    • Taku Kouro;
    • Satoru Motoyama;
    • Masatomo Miura;
    • Kazuma Fujita;
    • Yuka Igarashi;
    • Naoko Higashijima;
    • Norikazu Matsuo;
    • Hidetomo Himuro;
    • Feifei Wei;
    • Shun Horaguchi;
    • Kayoko Tsuji;
    • Yasunobu Mano;
    • Mitsuru Komahashi;
    • Haruhiro Saito;
    • Koichi Azuma;
    • Tetsuro Sasada
    Publication type:
    Article
    40

    Circulating IL-6 and not its circulating signaling components sIL-6R and sgp130 demonstrate clinical significance in NSCLC patients treated with immune checkpoint inhibitors.

    Published in:
    Frontiers in Cell & Developmental Biology, 2024, p. 1, doi. 10.3389/fcell.2023.1324898
    By:
    • Yoshiro Nakahara;
    • Taku Kouro;
    • Satoru Motoyama;
    • Masatomo Miura;
    • Kazuma Fujita;
    • Yuka Igarashi;
    • Naoko Higashijima;
    • Norikazu Matsuo;
    • Hidetomo Himuro;
    • Feifei Wei;
    • Shun Horaguchi;
    • Kayoko Tsuji;
    • Yasunobu Mano;
    • Mitsuru Komahashi;
    • Haruhiro Saito;
    • Koichi Azuma;
    • Tetsuro Sasada
    Publication type:
    Article
    41

    Circulating IL-6 and not its circulating signaling components sIL-6R and sgp130 demonstrate clinical significance in NSCLC patients treated with immune checkpoint inhibitors.

    Published in:
    Frontiers in Cell & Developmental Biology, 2024, p. 1, doi. 10.3389/fcell.2023.1324898
    By:
    • Yoshiro Nakahara;
    • Taku Kouro;
    • Satoru Motoyama;
    • Masatomo Miura;
    • Kazuma Fujita;
    • Yuka Igarashi;
    • Naoko Higashijima;
    • Norikazu Matsuo;
    • Hidetomo Himuro;
    • Feifei Wei;
    • Shun Horaguchi;
    • Kayoko Tsuji;
    • Yasunobu Mano;
    • Mitsuru Komahashi;
    • Haruhiro Saito;
    • Koichi Azuma;
    • Tetsuro Sasada
    Publication type:
    Article
    42
    43

    Randomized, Phase II study of pemetrexed plus bevacizumab versus pemetrexed alone after treatment with cisplatin, pemetrexed, and bevacizumab in advanced non‐squamous, non‐small cell lung cancer: TORG (thoracic oncology research group) 1321.

    Published in:
    Cancer Medicine, 2023, v. 12, n. 14, p. 14988, doi. 10.1002/cam4.6135
    By:
    • Kasai, Takashi;
    • Mori, Kiyoshi;
    • Nakamura, Yoichi;
    • Seki, Nobuhiko;
    • Ichikawa, Yasuko;
    • Saito, Haruhiro;
    • Kondo, Tetsuro;
    • Nishikawa, Kazuo;
    • Otsu, Satoshi;
    • Bessho, Akihiro;
    • Tanaka, Hiroshi;
    • Yamaguchi, Hiroyuki;
    • Kaburagi, Takayuki;
    • Imai, Hisao;
    • Mori, Keita;
    • Ohtake, Junya;
    • Okamoto, Hiroaki
    Publication type:
    Article
    44

    Randomized phase II trial of S‐1 plus cisplatin or docetaxel plus cisplatin with concurrent thoracic radiotherapy for inoperable stage III non‐small cell lung cancer.

    Published in:
    Cancer Medicine, 2021, v. 10, n. 2, p. 626, doi. 10.1002/cam4.3641
    By:
    • Shimokawa, Tsuneo;
    • Yamada, Kazuhiko;
    • Tanaka, Hiroshi;
    • Kubota, Kaoru;
    • Takiguchi, Yuichi;
    • Kishi, Kazuma;
    • Saito, Haruhiro;
    • Hosomi, Yukio;
    • Kato, Terufumi;
    • Harada, Daijiro;
    • Otani, Sakiko;
    • Kasai, Takashi;
    • Nakamura, Yoichi;
    • Misumi, Toshihiro;
    • Yamanaka, Takeharu;
    • Okamoto, Hiroaki
    Publication type:
    Article
    45

    Serum VEGF-A as a biomarker for the addition of bevacizumab to chemo-immunotherapy in metastatic NSCLC.

    Published in:
    Nature Communications, 2025, v. 16, n. 1, p. 1, doi. 10.1038/s41467-025-58186-7
    By:
    • Tanaka, Kentaro;
    • Sugisaka, Jun;
    • Shiraishi, Yoshimasa;
    • Watanabe, Yasutaka;
    • Daga, Haruko;
    • Azuma, Koichi;
    • Nishino, Kazumi;
    • Mori, Masahide;
    • Ota, Takayo;
    • Saito, Haruhiro;
    • Hata, Akito;
    • Sakaguchi, Tadashi;
    • Kozuki, Toshiyuki;
    • Akamatsu, Hiroaki;
    • Matsumoto, Hirotaka;
    • Tachihara, Motoko;
    • Wakuda, Kazushige;
    • Sato, Yuki;
    • Ozaki, Tomohiro;
    • Tsuchiya-Kawano, Yuko
    Publication type:
    Article
    46

    Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016.

    Published in:
    2018
    By:
    • Ikeda, Satoshi;
    • Kato, Terufumi;
    • Ogura, Takashi;
    • Sekine, Akimasa;
    • Oda, Tsuneyuki;
    • Masuda, Noriyuki;
    • Igawa, Satoshi;
    • Katono, Ken;
    • Otani, Sakiko;
    • Yamada, Kouzo;
    • Saito, Haruhiro;
    • Kondo, Tetsuro;
    • Hosomi, Yukio;
    • Nakahara, Yoshiro;
    • Nishikawa, Masanori;
    • Utumi, Keiko;
    • Misumi, Yuki;
    • Yamanaka, Takeharu;
    • Sakamaki, Kentaro;
    • Okamoto, Hiroaki
    Publication type:
    journal article
    47
    48

    Prognostic Significance of Plasma Neutrophil Extracellular Trap Levels in Patients with Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors.

    Published in:
    Biomedicines, 2024, v. 12, n. 8, p. 1831, doi. 10.3390/biomedicines12081831
    By:
    • Horaguchi, Shun;
    • Nakahara, Yoshiro;
    • Igarashi, Yuka;
    • Kouro, Taku;
    • Wei, Feifei;
    • Murotani, Kenta;
    • Udagawa, Seiichi;
    • Higashijima, Naoko;
    • Matsuo, Norikazu;
    • Murakami, Shuji;
    • Kato, Terufumi;
    • Kondo, Tetsuro;
    • Xiang, Huihui;
    • Kasajima, Rika;
    • Himuro, Hidetomo;
    • Tsuji, Kayoko;
    • Mano, Yasunobu;
    • Komahashi, Mitsuru;
    • Miyagi, Yohei;
    • Saito, Haruhiro
    Publication type:
    Article
    49
    50